Goldman Sachs Maintains Sell on FibroGen, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Paul Choi maintains a Sell rating on FibroGen (NASDAQ:FGEN) and lowers the price target from $16 to $2.
June 27, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs maintains a Sell rating on FibroGen and lowers the price target from $16 to $2.
Goldman Sachs' lowered price target on FibroGen indicates a bearish outlook for the stock. This could lead to a negative short-term impact on the stock price as investors may react to the revised target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100